Jefferies Group LLC reiterated their buy rating on shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) in a research report sent to investors on Saturday, July 22nd. Jefferies Group LLC currently has a $36.00 price objective on the stock.
Other analysts also recently issued research reports about the company. Cann reiterated a market perform rating on shares of Intellia Therapeutics in a research note on Monday, July 17th. Credit Suisse Group set a $24.00 price target on Intellia Therapeutics and gave the stock a buy rating in a research note on Wednesday, May 3rd. Wedbush reiterated an outperform rating and set a $25.00 price target on shares of Intellia Therapeutics in a research note on Monday, May 15th. TheStreet upgraded Intellia Therapeutics from a d+ rating to a c- rating in a research note on Thursday, July 6th. Finally, Chardan Capital assumed coverage on Intellia Therapeutics in a research note on Monday, March 27th. They set a buy rating and a $19.00 price target for the company. They noted that the move was a valuation call. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company currently has an average rating of Buy and an average target price of $24.83.
Shares of Intellia Therapeutics (NASDAQ NTLA) opened at 16.93 on Friday. The company’s 50 day moving average price is $16.45 and its 200 day moving average price is $14.30. Intellia Therapeutics has a one year low of $10.83 and a one year high of $24.90. The stock’s market capitalization is $611.38 million.
Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, August 3rd. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by $0.03. Intellia Therapeutics had a negative net margin of 204.48% and a negative return on equity of 22.70%. The firm had revenue of $5.90 million during the quarter, compared to analysts’ expectations of $5.83 million. The business’s quarterly revenue was up 40.5% compared to the same quarter last year. On average, equities analysts expect that Intellia Therapeutics will post ($1.74) earnings per share for the current year.
WARNING: “Intellia Therapeutics’ (NASDAQ:NTLA) Buy Rating Reiterated at Jefferies Group LLC” was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.com-unik.info/2017/08/12/intellia-therapeutics-nasdaqntla-buy-rating-reiterated-at-jefferies-group-llc-updated-updated.html.
In related news, major shareholder Venture Fund Ix L.P. Atlas sold 150,000 shares of the business’s stock in a transaction dated Tuesday, July 11th. The stock was sold at an average price of $16.24, for a total transaction of $2,436,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 12.80% of the stock is currently owned by insiders.
A number of institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its position in Intellia Therapeutics by 10.2% in the second quarter. Vanguard Group Inc. now owns 997,288 shares of the company’s stock valued at $15,957,000 after buying an additional 92,580 shares during the period. GMT Capital Corp purchased a new position in Intellia Therapeutics during the first quarter valued at approximately $4,657,000. ARK Investment Management LLC boosted its position in Intellia Therapeutics by 118.9% in the second quarter. ARK Investment Management LLC now owns 174,810 shares of the company’s stock valued at $2,797,000 after buying an additional 94,960 shares during the period. Acadian Asset Management LLC purchased a new position in Intellia Therapeutics during the first quarter valued at approximately $1,355,000. Finally, Paulson & CO. Inc. purchased a new position in Intellia Therapeutics during the first quarter valued at approximately $1,107,000. 46.88% of the stock is owned by hedge funds and other institutional investors.
About Intellia Therapeutics
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
What are top analysts saying about Intellia Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Intellia Therapeutics Inc. and related companies.